Our pipeline is focused on innovative therapeutic modalities and rationale combination treatment paradigms targeting difficult-to-treat cancers: 
- Development of the next-generation pipeline based on the latest science that addresses resistance mechanisms to Immune Checkpoint Inhibitors (ICIs)  
- Transformative clinical research that utilizes innovative study designs and novel biomarkers  
- Drug development to control lineage-dependent cancers with low sensitivity to existing therapies  
- Strengthen and optimize the collaboration between Clinical Development and the Eisai Discovery units  
- Exploration of biomarker-based tumor agnostic strategies  
- Harnessing immunoncology and understanding the tumor microenvironment in the pathogenesis of cancer